PACB Sales Up 11%
Pacific Biosciences (NASDAQ:PACB), a life sciences company specializing in DNA sequencing technology, published its latest earnings results for the fiscal second quarter ended June 30, 2025, on August 7, 2025. The headline news was a revenue figure of $39.8 million (GAAP), which surpassed analyst expectations of $36.62 million. Losses per share (Non-GAAP EPS) were less than predicted at $(0.13), beating the non-GAAP loss of $(0.17) per share that analysts had forecast. Both top- and bottom-line results improved over last year’s quarter, especially due to cost controls and higher margin from product mix. However, the company continues to post net losses and saw its cash balance shrink compared to the fiscal second quarter of 2024. The quarter showed progress in revenue and margin, with non-GAAP gross margin of 38%, but persistent cash flow and capital equipment placement challenges remain.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in the fiscal first quarter 2025 earnings report.
Pacific Biosciences develops and markets advanced DNA sequencing platforms for research use only. Its core product family includes long-read sequencing systems, such as the Revio sequencing instrument and the newer Vega benchtop sequencer. These systems allow users to decode genetic information with higher accuracy and greater context than traditional methods. The company primarily serves academic labs, commercial testing firms, and hospitals.
Source Fool.com
